Ultra-sensitivity at a low cost
Disease progression and resistance monitoring studies require low cost detection without sacrificing sensitivity. The MassARRAY® System can detect variants as low as 0.1% allele frequency at a low cost, making it ideally suited for disease monitoring.
While liquid biopsies provide easier access to tumor cells and DNA, they don’t necessarily provide enough. With just a few copies of circulating tumor DNA (ctDNA) per mL of plasma, you cannot afford to run multiple tests to detect all emerging resistance markers. The multiplexing capability of the UltraSEEK® chemistry makes it easy to detect over 100 variants, including insertions and deletions, using cfDNA from a single blood draw.
Liquid biopsy panel for the detection of variants in non-small cell lung cancer from cfDNA.Learn More
Liquid biopsy panel for the detection of EGFR resistance markers from cfDNA.Learn More
Liquid biopsy panel for the detection of variants in colorectal cancer from cfDNA.Learn More
Liquid biopsy panel for the detection of variants in melanoma from cfDNA.Learn More
Use DNA isolated from a variety of samples including blood plasma, circulating cell-free DNA and circulating tumor cells.
Getting started doesn’t have to be difficult. Get up and running quickly with the content you need. Create your own custom panels or let Assays by Agena scientists design, develop and functionally verify custom research use assays for you. Assays can be developed for targeted germline or somatic genotyping, translocations, copy number variants and more.Learn About Custom Assays
AMP 2019 Poster: Establishing the Sensitivity, Specificity, Interlaboratory Reproducibility, and Analytical Limit of Detection of the UltraSEEK™ Liquid Biopsy Application Using Well-Defined Seraseq Reference Material